L2pB1 cells are essential for the inhibition of 3D tumor spheroids by syngeneic peritoneal immune cells

• Main Author: Bootwala, Ali Habib
• Other Authors: Zhong, Xuemei
• Language: en_US
• Published: 2019
• Subjects: Immunology; 3D tumor spheroid; B1a cell; B lymphocyte; L2pB1; PD-L2; Programmed death ligand 2
• Online Access: https://hdl.handle.net/2144/34840

INTRODUCTION: Programmed Death Ligand 2 positive B1 cells (L2pB1) cells have a unique immunoglobulin repertoire that is poly-reactive to self-antigens and have previously been shown to have an essential role in autoimmunity. The active accumulation of L2pB1 cells inside tumors grown in vivo led us to hypothesize that this subpopulation of B1a cells may play a role in the immunosurveillance of cancer. Here, we report our investigation of the role of L2pB1 cells in the antitumor response using a three dimensional (3D) murine melanoma and colon cancer models. Our results showed that the depletion of L2pB1 cells rendered the loss of tumor inhibition effects of the syngeneic peritoneal immune cells. METHODS: Lymphocytes were collected from L2pB1 cell depleted and non-depleted peritoneal cavity washout (PCW) from an inducible knockout mouse model. Then tumor spheroids were incubated with PCW cells. Spheroid cross-sectional area (CSA) and volume were measured using a Celigo plate imager and Keyence fluorescence microscope. RESULTS: Tumor spheroid growth was significantly inhibited following incubation with syngeneic PCW but not with splenocytes. Depletion of L2pB1 significantly attenuated the tumor-inhibition effect and showed a negligible difference from the untreated control. This loss of tumor inhibition indicated that L2pB1 cells are essential for the tumor-inhibition effects of autologous peritoneal immune cells. CONCLUSIONS: These findings demonstrate the robust anti-tumor function of L2pB1 cells. In particular, peritoneal L2pB1 cells play an essential role in cancer inhibition. Future studies into the activation and antigen presentation pathways of L2pB1 cells could lead to novel immunotherapy of cancer.